BACKGROUND: Since its debut in 2011, cell-free fetal DNA screening has undergone rapid expansion with respect to both utilization and coverage. However, conclusive data regarding the clinical validity and utility of this screening tool, both for the originally included common autosomal and sex-chromosomal aneuploidies as well as the more recently added chromosomal microdeletion syndromes, have lagged behind. Thus, there is a continued need to educate clinicians and patients about the current benefits and limitations of this screening tool to inform pre-and posttest counseling, pre/perinatal decision making, and medical risk assessment/management. OBJECTIVE: The objective of this study was to determine the positive predictive value and false-positive rates for different chromosomal abnormalities identified by cell-free fetal DNA screening using a large data set of diagnostic testing results on invasive samples submitted to the laboratory for confirmatory studies. STUDY DESIGN: We tested 712 patient samples sent to our laboratory to confirm a cell-free fetal DNA screening result, indicating high risk for a chromosome abnormality. We compiled data from all cases in which the indication for confirmatory testing was a positive cell-free fetal DNA screen, including the common trisomies, sex chromosomal aneuploidies, microdeletion syndromes, and other large genome-wide copy number abnormalities. Testing modalities included fluorescence in situ hybridization, G-banded karyotype, and/or chromosomal microarray analysis performed on chorionic villus samples, amniotic fluid, or postnatally obtained blood samples. Positive predictive values and false-positive rates were calculated from tabulated data.
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RESULTS:
The positive predictive values for trisomy 13, 18 , and 21 were consistent with previous reports at 45%, 76%, and 84%, respectively. For the microdeletion syndrome regions, positive predictive values ranged from 0% for detection of Cri-du-Chat syndrome and Prader-Willi/ Angelman syndrome to 14% for 1p36 deletion syndrome and 21% for 22q11.2 deletion syndrome. Detection of sex chromosomal aneuploidies had positive predictive values of 26% for monosomy X, 50% for 47,XXX, and 86% for 47,XXY. CONCLUSION: The positive predictive values for detection of common autosomal and sex chromosomal aneuploidies by cell-free fetal DNA screening were comparable with other studies. Identification of microdeletions was associated with lower positive predictive values and higher false-positive rates, likely because of the low prevalence of the individual targeted microdeletion syndromes in the general population. Although the obtained positive predictive values compare favorably with those seen in traditional screening approaches for common aneuploidies, they highlight the importance of educating clinicians and patients on the limitations of cell-free fetal DNA screening tests. Improvement of the cell-free fetal DNA screening technology and continued monitoring of its performance after introduction into clinical practice will be important to fully establish its clinical utility. Nonetheless, our data provide valuable information that may aid result interpretation, patient counseling, and clinical decision making/management.
Key words: amniocentesis, cell-free DNA, microdeletion syndrome, NIPT, noninvasive prenatal screening, noninvasive prenatal testing, prenatal diagnosis, trisomy 13, trisomy 18, trisomy 21, 47,XXX, 47,XXY, 47,XYY N oninvasive prenatal screening (NIPS) using massively parallel sequencing analysis of cell-free fetal DNA (cffDNA) in maternal plasma, which contains cell-free fetal DNA originating from the trophoblast mixed with cell-free maternal DNA, has become one of the most quickly adopted screens in history.
Following integration into clinical practice in 2011, multiple clinical validation studies in both high-and lowrisk populations have shown good performance of cffDNA screening for the detection of the most common autosomal aneuploidies including trisomy 21 (T21), trisomy 13 (T13), and trisomy 18 (T18). [1] [2] [3] [4] [5] [6] [7] [8] [9] However, the scope of cffDNA screening is expanding beyond these conditions with platforms that now include subchromosomal copy number changes (microdeletions), rare autosomal trisomies, and sex-chromosomal disorders, conferring an urgent need for large-scale clinical validation studies of the general obstetric population. [10] [11] [12] While subchromosomal deletions and duplications are collectively relatively common, with detection of clinically significant microdeletions and microduplications in up to 1e1.7% of structurally normal pregnancies at increased risk for common aneuploidies because of age or abnormal maternal serum screening results, 13, 14 each is individually quite rare. Although advanced maternal age and a positive maternal serum screen result are not factors known to be associated with an increased risk for copy number variants, it is not yet certain whether this is the true burden of pathogenic copy number Original Research ajog.org variants (CNVs) in an unselected prenatal low-to average-risk population.
As with any rare condition, a screen for microdeletion syndromes is expected to have low positive predictive values (PPV) and high false-positive rates. Early reported experiences with confirmatory testing highlighted both high discordance between cffDNA-based microdeletion detection and confirmation studies as well as an atypical nonpathogenic 22q11.2 deletion that resulted in a positive cffDNA screening test for DiGeorge syndrome. 15, 16 However, sample sizes in these studies have been small and data are largely unpublished.
While microdeletion disorders manifest significant postnatal morbidity and mortality, prenatal phenotypic evidence is often subtle or absent on the basis of routine prenatal ultrasound. This is in part due to phenotypic variability and to the fact that even if present, <40% of fetal structural malformations are currently identified on second-trimester anatomy scan. 17 Further complicating prenatal screening and diagnosis of microdeletion syndromes is the absence of known risk factors in most cases. Unlike aneuploidy, which is known to be positively correlated with advancing maternal age, neither age nor any other known patient demographic is known to increase microdeletion syndrome risk. Thus, effective alternate approaches to identify pregnancies affected with or at high risk for clinically significant microdeletion and microduplication syndromes would be valuable to optimize management and counseling. However, given the current relative paucity of data on the clinical performance of cffDNA screening for these, the genetic counseling for positive screening results is currently challenging for the clinician and patient. 18 In addition, the microdeletion syndromes included on the cffDNA screening panels are highly selected and do not cover the full spectrum of deletions found prenatally. 13 This has led professional societies to recommend against the use of cffDNA screening for common microdeletions. 19 As with the integration of any new technology into clinical practice, challenges arise that must be addressed to maximize clinical utility. As cffDNA screening becomes the new standard of care, more studies of the validity of each component are needed to guide clinicians in when to recommend testing and how to interpret results. In the current study, we examined 712 confirmatory diagnostic studies performed on patients who have received an abnormal or inconclusive cffDNA screening result, including 52 cases in whom cffDNA screening was positive for a microdeletion, and compare our findings with the published literature.
Materials and Methods
We performed and analyzed follow-up diagnostic testing on samples from 712 women sent to Baylor Genetics following abnormal cffDNA screening results. Initial cffDNA screening was ordered on maternal blood samples by the referring physician and performed by a variety of commercial laboratories including Ariosa Diagnostics, BGI, Natera, Sequenom, and Illumina, according to their specific methodologies. In many cases we were not provided the information on the laboratory that performed the NIPS testing, and because of the retrospective deidentified nature of the study, we are not able to recontact the providers to retrieve this information.
All follow-up, confirmatory diagnostic testing was performed at Baylor Genetics either prenatally (on chorionic villus samples or amniotic fluid) or postnatally on infant blood samples and included fluorescence in situ hybridization, karyotype, and chromosomal microarray analysis (CMA). CMA was performed using custom Baylor Genetics oligonucleotide arrays, manufactured by Agilent Technologies, Inc (Santa Clara, CA), according to the manufacturer's instructions.
Data were analyzed using a custom web-based software platform as described previously. 20, 21 Aneuploidy fluorescence in situ hybridization and karyotype analyses were performed according to standard methods. Retrospective review of clinical data was carried out under Baylor College of Medicine institutional review boardeapproved waiver of consent protocol for deidentified data (number H-29583).
For the analysis phase, aneuploid cases categorized as true positives (TPs) included those with complete concordance as well as those meeting the following criteria: high-level mosaicism for the aneuploidy flagged on cffDNA screening (ie, NIPS positive for T13 and confirmatory testing demonstrating high-level mosaic T13), partial concordance (ie, NIPS positive for T18, confirmatory testing demonstrating trisomy for a portion of chromosome 18), and incomplete concordance (ie, NIPS positive for both T13 and T18, confirmatory testing demonstrates T13 only).
True negative aneuploidy cases were defined as those with complete discordance. For the microdeletion syndromes, TPs and false positives were those with respective full concordance or full discordance between cffDNA screening and confirmatory testing. PPV was calculated as the number of cases for which cffDNA screening and confirmatory diagnostic testing were concordant (TP), divided by the number of cases with positive cffDNA screening (TP plus false positive), multiplied by 100.
Results
Of the 712 patient samples submitted to our laboratory from April 2012 to June 2017, there were 492 cases with positive cffDNA screens for the common autosomal trisomies (T13, T18, T21) (69%), 138 positive screens for sex chromosomal abnormalities (19%), 52 positive screens for microdeletion syndromes (7.3%), 4 cases with positive screens indicating large genomic deletions/duplications (0.6%), and 9 positive screens for multiple abnormal findings in the same sample (1.3%).
Cases of suspected aneuploidy
The cffDNA screening accurately identified the common autosomal aneuploidies (T13, T18, T21) and the sex chromosomal abnormalities in more than two thirds of the cases in our study (68%), but the performance varied based on the specific abnormality. The most common abnormal cffDNA screen
This category also had the highest PPV of any of the autosomal aneuploidies (84%), consistent with previously reported studies. 4, 8, [22] [23] [24] [25] The PPV for T18 was also high at 76%; however, it dropped off significantly for T13 (45%) and monosomy X (26%). While the number of cffDNA screen-positive cases of XXY was relatively small (n ¼ 22), the calculated PPV was high at 86%. Among the sex chromosome aneuploidies included in the true positives were 12 mosaic cases, one of which was mosaic with a ring X chromosome and the other with trisomy X as well as 1 partial monosomy X and 2 cases of isochromosome X.
Our cohort also included 12 patients with positive cffDNA screening results for less common aneuploidies (ie, monosomies 13 and 18 and trisomies for chromosomes 7, 9, 14, and 16). For these categories, the sample size is too small to calculate PPVs; however, we noted that none of the 5 cffDNA screen-positive monosomy (13 and 18) cases were confirmed, and only 1 of the 6 cases of less common trisomies (trisomy 16) was confirmed ( Table 1 ). Given that trisomy 16 is the most common trisomy leading to miscarriage, we attribute this low frequency to the limited number of cffDNA screening options that include this chromosome.
Cases of suspected microdeletion or genome-wide deletion/ duplication
Microdeletion syndromeepositive cases showed a higher discordance than for common aneuploidies (Table 2) , and although the low number of cases in our data set hinder our ability to draw meaningful PPVs for each individual microdeletion, we nevertheless attempt to draw a comparison with the results of other published studies in Table 3 .
The combined PPV for all microdeletion-positive cffDNA screen cases in our data set was 13%, while the PPV for the most frequent microdeletion in our data set (22q11.2/DiGeorge syndrome deletion, n ¼ 28) was 21%. Accordingly, our data showed lower PPVs across all 4 of the commonly reported microdeletion syndrome regions compared with those for common aneuploidies, similar to previously published reports (Table 3) . 10, 11, 15, 26 In addition to the common microdeletion syndromes, there were 4 cases in which the results of a genome-wide cffDNA screen identified a large genomic imbalance. These included the following: 1 positive screen for a 10.8 Mb gain and 13.1 Mb loss of chromosome 11p15.2p14. 3 and 11p14.3p12, 
Cases with atypical cffDNA screening results
There were 9 cases in which cffDNA screening results indicated multiple findings, including 8 cases with multiple aneuploidies and 1 case with both a trisomy and a microdeletion. None of these cases had complete concordance based on diagnostic testing, but in 4 cases 1 of the predicted aneuploidies was confirmed (2 cases of T13, 1 T18, and 1 T21). The remaining 5 cases returned normal clinical diagnostic results.
Recently there has been growing interest in maternal incidental findings as a result of positive cffDNA screening, 27 specifically as it relates to positive screens for multiple aneuploidies and the association with occult maternal malignancy. [28] [29] [30] While our data set includes cases of positive cffDNA screening for multiple aneuploidies, the lack of complete maternal clinical histories precluded further investigation into this association.
Comment

Principal findings and clinical implications
To our knowledge, this study represents the largest data set of its kind looking at PPVs of cffDNA screening, including for microdeletions. Overall, our data are consistent with previously published studies with detection rates that vary, depending on the chromosomal imbalance, but we noted higher false-positive rates for microdeletion syndrome regions compared with common aneuploidies (Tables 1 and 2) .
Among the sex chromosome aneuploidies, the PPV for monosomy X based on 100 screen-positive cases was 26%, similar to that reported by Sahoo et al. 15 PPVs for cffDNA screening for other sex chromosome aneuploidies were substantially better at 86% for XXY and 50% for XXX syndrome, although sample sizes were small (n ¼ 22 and n ¼ 12, respectively). While the number of cases with a positive cffDNA screen for XYY was too low to accurately calculate PPV (only 4 cases), all of them were confirmed by invasive testing.
Interestingly, a small study by Wang et al 31 reported that 8.6% of positive cffDNA results for sex chromosome aneuploidies were due to maternal sex chromosome mosaicism. More research is needed in this area to aid interpretation of these results, although they underscore the importance of further work-up following a positive cffDNA screen for a sex chromosome aneuploidy.
For the selected microdeletion syndromes (Cri du Chat/5p-syndrome, Prader Willi/Angelman syndromes, 22q11del/DiGeorge syndrome, and 1p36 deletion syndrome), our data show lower PPVs (0e21%) and higher falsepositive rates (79e100%) than for common aneuploidies. This reproduces and expands on data reported previously by Sahoo et al. 15 Although the methodologies were different and as such arguably less representative of a true patient population, Wapner et al 26 also reported low PPV for these syndromes in their analysis.
It is notable that the report by Helgeson et al 11 describes a much higher PPV for microdeletion cffDNA screening compared with other studies, including ours (Table 3) . One possible reason for this is that the study includes cases that were not diagnostically confirmed but rather suspected because of the clinical findings, which could have an impact on the calculated PPV.
Reasons proposed previously for false-positive cffDNA screening results include placental mosaicism, 32 vanishing twin syndrome, 33 maternal chromosomal abnormalities, 2, 34 and neoplastic conditions. [28] [29] [30] Additional factors such as fetal fraction, maternalfetal admixture, and genomic resolution present challenges to this technology, particularly in the case of microdeletions in which the sensitivity may depend on the size of the fetal copy number variant. Furthermore, the frequency of the condition in the population being tested is critical for calculating PPV, with the value increasing with higher prevalence of the condition. Thus, it is not surprising that PPVs are higher for the common aneuploidies compared with the rare microdeletion syndromes, even in a larger data set.
Strengths and weaknesses
Likelihood ratios are important metrics of clinical utility and help with the counseling of patients, and thus, one limitation of our study of samples submitted to a referral confirmatory testing center is that we do not have access to the pregnancy outcomes of negative cffDNA screening results or data on the total number of women who underwent screening. Therefore, we are not able to compute sensitivity and specificity, which are needed to determine likelihood ratios. Considering the commercial nature of integration of cffDNA screening into clinical practice, with variable and evolving platforms being offered by individual providers, obtaining these data is challenging. Unless or until large research studies are performed, or (self)-regulation incentivizes laboratory providers of cffDNA screening tests and those offering these tests clinically to collect and submit all outcomes data into a common registry, this goal will be difficult to achieve. Until such time, the information on PPVs, if presented and interpreted taking into account such limitations, can be valuable in counseling until such data are available.
Additional limitations to our data include that, as a confirmatory testing site, we lacked clinical context/indication for cffDNA screening in the majority of cases. We also do not have clinical data to assess for possible other explanations for a positive cffDNA screen such as co-twin demise, disorders of sexual differentiation, or a history of male-donor maternal organ transplants. Furthermore, methodologies used for cffDNA screening vary, are proprietary, and are subject to change.
Commercially available methodologies are typically categorized into quantitative methods, which include the generation of a z-score using either low coverage massively parallel Sanger sequencing and/or targeted sequencing and, nonquantitative single-nucleotide polymorphismebased methods. Once the initial analysis is generated, processing algorithms are used that are again not publicly available. While we may expect that the nuances of cffDNA screening methodology may have a bearing on the PPV, until such time that this methodology is standardized and publicly available, the clinician and patient interpretation of data is best based on pooled data. This most closely reflects the heterogeneity of testing performed across the general population of pregnant women.
Conclusion with future implications
The data presented here remind us that cffDNA screening is in fact a screen, with a test performance that is currently below that of diagnostic tests. Patients should be made aware of the limitations of the screen, and counseling should include the option of diagnostic testing along with risks and benefits of each option, keeping in mind the frequency of microdeletions found by CMA and the currently updated risk numbers on procedureinduced pregnancy losses. 35 Furthermore, cffDNA screening for rare aneuploidies and microdeletions is not yet recommended by professional societies (American College of Obstetricians and Gynecologists/Society for Maternal-Fetal Medicine, American College of Medical Genetics and Genomics), and the currently offered cffDNA screening focuses on only a few selected microdeletions and most do not currently detect duplications.
Nevertheless, expanded cffDNA screening is already integrated into clinical practice, and therefore, it is important to inform the clinicians through data, such as those presented here. Despite the controversy that surrounds cffDNA screening, both sides agree that better methods for prenatal pre-and posttest counseling are needed so that parents can better understand the choices they are making. 36 PPV is vitally important because it indicates the probability that a positive test result represents a true fetal abnormality: if it is low, the screen's value is limited in this regard. However, the clinical utility of any test, and particularly in the case of rare disease syndromes, even with a low PPV, is still highly valuable in the event of a high negative predictive value, affording the clinician and patient a commensurately high degree of reassurance when the screening returns negative results.
Wapner et al. suggested negative predictive value of >99.99% for these microdeletion syndromes. 26 Were these results to be generally reproducible, they would provide a strong incentive to recommend cffDNA screening for these conditions. The data reported here support the need for increased public awareness of the screening nature and limitations of the current expanded cffDNA technology. n
